There’s one endpoint that the booming biopharma industry has failed at miserably: financial toxicity
One of the big themes in R&D over the past few years has been the onslaught of spending on developing new oncology drugs. The FDA …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.